183673-71-4Relevant articles and documents
LIM KINASE INHIBITORS
-
Page/Page column 36, (2015/11/02)
The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In particular, the present invention relates to new LIMK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said Compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Ophthalmic and intestinal diseases.
A convenient preparation of an orthogonally protected c,c-disubstituted amino acid analog of lysine: 1-tert-butyloxycarbonyl-4-((9-fluorenylmethyloxycarbonyl)amino)-piperidine-4-carboxylic acid: [1,4-piperidinedicarboxylic acid, 4-[[(9H-fluoren-9-ylmethyloxy)carbonyl]amino]-, (1,1-dimethylethyl) ester]
Hammarstr?m, Lars G. J,Fu, Yanwen,Vail, Sidney,Hammer, Robert P,McLaughlin, Mark L.,Danheiser, Rick L,Hayes, Martin E.
, p. 213 - 224 (2017/09/23)
-
Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands
Bleicher, Konrad H.,Wuethrich, Yves,De Boni, Maxime,Kolczewski, Sabine,Hoffmann, Torsten,Sleight, Andrew J.
, p. 2519 - 2522 (2007/10/03)
The combination of the 3,5-bis(trifluoromethyl)phenyl group with a spirohydantoin motive as a central scaffold was the basis for the design of a combinatorial library targeted towards the neurokinin-1 receptor. A solution- and solid-phase procedure is described and binding affinities of representative compounds presented.